ClinicalTrials.gg
CompletedNCT06675175Updated Nov 25, 2025

A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

A Phase 1 interventional study of AZD4144 and Placebo in Chronic Kidney Disease and Atherosclerotic Cardiovascular Disease, sponsored by AstraZeneca. Completed at 15 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Renal Insufficiency, Chronic by AstraZeneca — 6 open to participants now, 11 under way, 5 of them phase 3. Renal Insufficiency, Chronic · AstraZeneca.

Enrollment
25th of 38
29 · median 170
Started
2024
with 7 others
Phase 1
16 of 54
1 open now
Registered
42nd of 54
by date

Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 25th largest by enrollment of the 38 interventional ones that give a count, is one of 8 that started in 2024, is one of 16 in phase 1, and was the 42nd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 54 studies in Renal Insufficiency, Chronic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Renal Insufficiency, Chronic by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).

Read the detailed description

This is a Phase 1b, randomized, double blind, placebo-controlled study and will be conducted in participants with established ASCVD and CKD with persistent inflammation (High-sensitivity C-reactive protein [hsCRP] > 2 mg/L and eGlomerular filtration rate [eGFR] ≥ 30 to \< 60 mL/min/1.73m2). The participants will be randomized in the 1:1 ratio to either receive treatment with AZD4144 or placebo.

The study will be comprised of:

  • A screening period of 28 days
  • Treatment period where each participant will either receive oral dose of AZD4144 or placebo for 28 days.
  • A follow-up visit (Day 35 ±1) and a Final Follow-up (on Day 56±1) post first dose administration.

The total duration of the study will be approximately 12 weeks.

03

Conditions studied

  • Chronic Kidney Disease
  • Atherosclerotic Cardiovascular Disease

Keywords

  • Cardiorenal disease
  • Estimated glomerular filtration rate
  • Nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) cryopyrin
  • inflammatory cytokines
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with established ASCVD history of one or more of the following

    1. Prior Myocardial infarction (MI) (>60 days from index event) or coronary revascularization procedure like coronary stenting or Coronary artery bypass graft (CABG)
    2. Prior ischemic stroke (>60 days from index event)
    3. Symptomatic Peripheral Arterial Disease
  • Chronic kidney disease defined as eGlomular filtration rate () ≥ 30 to \< 60 mL/min/1.73 m2
  • Serum hsCRP > 2 mg/L
  • ≥ 18 to ≤ 45 kg/m2
  • All females must have a negative pregnancy test at the Screening Visit and at the randomization visit

    1. Sexually active male participants with partner of must adhere to the methods
    2. Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception
    3. Females of non-childbearing potential must be confirmed at the Screening visit

Key Exclusion Criteria:

  • History of within the last 5 years
  • History of MI, coronary revascularization, stroke or revascularization for peripheral arterial disease in the 60 days prior to Screening
  • Active systemic infection within 30 days
  • active and chronic infections within 60 days prior to randomization
  • Clinically significant recurrent infection (≥ 2× during the last 12-month period).
  • Renal transplant participants, participants on dialysis, and those with a history of acute kidney injury in the past 12 month
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    AZD4144

    Participants will receive oral dose of AZD4144 for 28 days.

    Drug: AZD4144

  • Placebo comparator
    Placebo

    Participants will receive oral dose of Placebo for 28 days.

    Other: Placebo

Interventions

  • Oral solution of AZD4144 will be given to randomised participants as per the arm they have been assigned.

  • OtherPlacebo

    Placebo will be given orally to randomized participants as per the arm they are assigned.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    The safety and the tolerability of AZD4144 compared with placebo will be evaluated.

    Time frame: From first dose (Day 1) until Follow-up (Day 56±1)

  2. Relative change from baseline to 4 weeks in systemic Interleukin-6 (IL-6) levels

    The effect of AZD4144 on circulating inflammatory biomarker IL-6 compared with placebo will be evaluated.

    Time frame: Day 1 to Day 28

Secondary outcomes

  1. Relative change from baseline to 4 weeks in systemic IL-18 and High-sensitivity C-reactive protein (hsCRP) levels

    The effect of AZD4144 on circulating inflammatory biomarkers IL-18 and hsCRP compared with placebo will be evaluated.

    Time frame: Day 1 to Day 28

  2. Maximum plasma drug concentration (Cmax)

    The Cmax after administration of AZD4144 in participants with ASCVD and CKD will be evaluated.

    Time frame: Day 1 to Day 28 (pre-dose), Day 1 and Day 22±1 (post-dose)

  3. Time to reach maximum observed concentration (tmax)

    The tmax after administration of AZD4144 in participants with ASCVD and CKD will be evaluated.

    Time frame: Day 1 to Day 28 (pre-dose), Day 1 and Day 22±1 (post-dose)

  4. Observed lowest concentration before the next dose is administered (Ctrough)

    The Ctrough after administration of AZD4144 in participants with ASCVD and CKD will be evaluated.

    Time frame: Day 1 to Day 28 (pre-dose), Day 1 and Day 22±1 (post-dose)

07

Study locations

15 sites
  • Research Site
    Glendale, California 91203, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Miami, Florida 33125, United States
  • Research Site
    Port Orange, Florida 32127, United States
  • Research Site
    Tampa, Florida 33603, United States
  • Research Site
    Farmington Hills, Michigan 48334, United States
  • Research Site
    The Bronx, New York 10455, United States
  • Research Site
    Sherman, Texas 75092, United States
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Gyöngyös, 3200, Hungary
  • Research Site
    Kistarcsa, 2143, Hungary
  • Research Site
    Bucharest, 11658, Romania
  • Research Site
    Cluj-Napoca, 400006, Romania
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Oct 2025, 10 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 10 months is above that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 5, 2024
StartActual
Dec 9, 2024
Primary completionActual
Oct 27, 2025
CompletionActual
Oct 27, 2025
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06675175
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Dec 9, 2024
Primary completion
Oct 27, 2025
Completion
Oct 27, 2025
Last update
Nov 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berzanoflast

Start the discussion